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The following sections are direct quotes from Cerny and Cerny ( *Hum Vaccin*. 2009;5(4):200--205).

-   The second, third, and fourth sentences of the abstract, as well as the last paragraph of the abstract, except for the second sentence (pp. 211)

-   'Vaccines against nicotine' (pp. 217)

-   The first two paragraphs in 'Vaccines against nicotine under evaluation in clinical trials' (pp. 218) with the exception of the last sentence in the second paragraph

-   'Cytos AG, Schlieren Switzerland' (pp. 218)

-   'Phase II study of vaccine NIB002' (pp. 218)

-   'Celtic pharma holdings LP' (pp. 219) with the exception of the third-to-last and fourth-to-last sentences

-   'Nabi Inc' (pp. 220) with the exception of the last two sentences

-   'Chilka Ltd and other competitors developing nicotine vaccines' (pp. 220)

-   'Further developments to expect' (pp. 220)
